Thursday, April 30, 2020 3:17:56 PM
As usual - I think that the ridicule is being sourced by the same nagging and lingering concerns.
1) The IND and beginning of testing of the Shingles-treatment has been 'promised' for years now and still isn't underway. This makes it easy for the typical detractor sources to generate ridicule.
2) The 'shift' (at least perceived as a shift) to the flavor of the month (in this case coronavirus treatments) fits the old pattern from the last decade for NNVC - which makes ridicule easy to do.
3) NNVC (to our knowledge) hasn't even begun negotiating with Diwan's private companies for a license for a coronavirus drug application - which again - makes ridiculing the company an easy task.
And in the meantime the company continues to appear to spin it's wheels and slowly drain out money.
1) The IND and beginning of testing of the Shingles-treatment has been 'promised' for years now and still isn't underway. This makes it easy for the typical detractor sources to generate ridicule.
2) The 'shift' (at least perceived as a shift) to the flavor of the month (in this case coronavirus treatments) fits the old pattern from the last decade for NNVC - which makes ridicule easy to do.
3) NNVC (to our knowledge) hasn't even begun negotiating with Diwan's private companies for a license for a coronavirus drug application - which again - makes ridiculing the company an easy task.
And in the meantime the company continues to appear to spin it's wheels and slowly drain out money.
“The two most powerful warriors are patience and time.”
- Leo Nikolaevich Tolstoy
Recent NNVC News
- Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides • ACCESS Newswire • 04/21/2026 12:30:00 PM
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2025 09:07:54 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/29/2025 08:33:17 PM
